Frequency Electronics reported earnings of 34 cents per share for the fourth quarter, up from 28 cents per share in the ...

Frequency Therapeutics is an interesting biotech company that I first looked at because of my interest in companies developing therapies to treat the diseases of aging.As their name suggests ...

What happenedShares of Frequency Therapeutics (NASDAQ: FREQ) were crashing 74.9% as of 11:07 a.m. EDT on Tuesday. The huge drop came after the company announced disappointing top-line interim ...

Frequency Therapeutics is a small biotech company focused on bringing to market its proprietary therapy to treat hearing loss, an increasingly large problem as the average age of the world’s ...

Frequency Therapeutics is going back to the drawing board. After showing promise in phase 1, four dosing regimens of its hearing loss treatment did no better than placebo in a phase 2a study.

Pooled data from three of Frequency Therapeutics trials on FX-322 showed a pattern of response. A Phase 2 clinical trial showed no effect compared to placebo, but leadership argues the study ...

Frequency was testing its hearing loss therapy, FX-322, in patients who have sensorineural hearing loss (SNHL), which is caused by damage to the tiny hair cells in the ear that turn vibrations ...

Frequency Therapeutics announced it will scrap development of a drug called FX-322 after testing failed to show improvement in speech perception in people with noise-induced sensorineural hearing ...

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a clinical stage biotechnology company, today announced positive results from a Phase 1/2 safety trial to evaluate FX-322, an ...

Exploring FX-322: Innovative Hearing Loss Therapy. On July 17, Astellas Pharma announced that it had entered into an agreement with Frequency Therapeutics to co-develop and commercialise FX-322, a ...

WOBURN, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, a company developing a pipeline of new drugs that activate progenitor cells within the body, today announced the closing of a $32 million ...

Korro Bio plans a reverse merger with Frequency Therapeutics to fund clinical studies of its lead candidate, designed to treat alpha-1 antitrypsin deficiency (AATD) in the liver.